Literature DB >> 7947376

Risk stratification after myocardial infarction: role of electrical instability, ischemia, and left ventricular function.

A Bayés-de-Luna1, X Viñolas, J Guindo, A Bayés-Genis.   

Abstract

The problem of risk stratification after myocardial infarction is reviewed. There are three major complications: new ischemic events, congestive heart failure, and malignant arrhythmias and sudden death, related to the presence of residual ischemia, left ventricular dysfunction, and electrical instability. The bidirectional interactions among these three factors is analyzed. The risk is in the middle of a triangle, the three angles of which are the above-mentioned factors. All the "satellite" factors that appear from all three angles are presented. Furthermore, the most important parameters and techniques employed to detect risk, multifactorial approach of risk stratification, and changes of risk stratification in the thrombolytic era are briefly reviewed.

Entities:  

Mesh:

Year:  1994        PMID: 7947376     DOI: 10.1007/bf00877318

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  44 in total

1.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.

Authors:  A Bayés de Luna; P Coumel; J F Leclercq
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

Review 2.  A potential role of calcium ions in early ischemic and reperfusion arrhythmias.

Authors:  L H Opie; W A Coetzee; S C Dennis; F T Thandroyen
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction.

Authors:  E S Gang; A S Lew; M Hong; F Z Wang; C A Siebert; T Peter
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

5.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction.

Authors:  J T Bigger; J L Fleiss; R Kleiger; J P Miller; L M Rolnitzky
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

6.  Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography.

Authors:  D L Kuchar; C W Thorburn; N L Sammel
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

7.  Effects of early reperfusion in acute myocardial infarction on arrhythmias induced by programmed stimulation: a prospective, randomized study.

Authors:  I E Kersschot; P Brugada; M Ramentol; M Zehender; B Waldecker; W G Stevenson; A Geibel; C De Zwaan; H J Wellens
Journal:  J Am Coll Cardiol       Date:  1986-06       Impact factor: 24.094

8.  Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: is there a need for coronary angiography? European Cooperative Study Group.

Authors:  A E Arnold; M L Simoons; J M Detry; R von Essen; F Van de Werf; J W Deckers; J Lubsen; M Verstraete
Journal:  Eur Heart J       Date:  1993-03       Impact factor: 29.983

9.  Silent myocardial ischemia and infarction: insights from the Framingham Study.

Authors:  W B Kannel
Journal:  Cardiol Clin       Date:  1986-11       Impact factor: 2.213

10.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

Authors:  R DiBianco; R Shabetai; W Kostuk; J Moran; R C Schlant; R Wright
Journal:  N Engl J Med       Date:  1989-03-16       Impact factor: 91.245

View more
  1 in total

Review 1.  QT dynamics and variability.

Authors:  Wojciech Zareba; Antoni Bayes de Luna
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-04       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.